A 37-year-old man underwent lobectomy of the right liver for granulocyte colony-stimulating factor (G-CSF) producing hepatocellular carcinoma accompanying type B hepatitis. Within two months after the surgery, lung metastases were revealed and administration of sorafenib was begun, however, the lung metastases continued to enlarge. Changing the patient's medication to tegafur-uracil provided remarkable reduction of the lung metastases. The patient is alive two years after diagnosis and receives outpatient chemotherapy. We concluded that this case is valuable with regard to the extreme rarity of G-CSF producing hepatocellular carcinoma and its successful treatment in this case.

Download full-text PDF

Source

Publication Analysis

Top Keywords

producing hepatocellular
12
hepatocellular carcinoma
12
lung metastases
12
successful treatment
8
granulocyte colony-stimulating
8
colony-stimulating factor
8
carcinoma accompanying
8
accompanying type
8
type hepatitis
8
g-csf producing
8

Similar Publications

Fibrolamellar Hepatocellular Carcinoma (FLC) is a rare liver cancer characterized by a fusion oncokinase of the genes DNAJB1 and PRKACA, the catalytic subunit of protein kinase A (PKA). A few FLC-like tumors have been reported showing other alterations involving PKA. To better understand FLC pathogenesis and the relationships among FLC, FLC-like, and other liver tumors, we performed a massive multi-omics analysis.

View Article and Find Full Text PDF

A hepatocellular carcinoma model with and without parenchymal liver damage that integrates technical and pathophysiological advantages for therapy testing.

Pharmacol Res

December 2024

Department of Dermatology, University Medical Center of the Johannes Gutenberg-University, Langenbeckstrasse 1, 55131 Mainz, Germany; Department of Medicine II, Saarland University Medical Center, Saarland University, Kirrberger Strasse 100, 66123 Saarbrücken, Germany. Electronic address:

Hepatocellular Carcinoma (HCC) is the most common form of primary liver cancer, with cirrhosis being its strongest risk factor. Interestingly, an increasing number of HCC cases is also observed without cirrhosis. We developed an HCC model via intrasplenic injection of highly tumorigenic HCC cells, which, due to cellular tropism, invade the liver and allow for a controllable disease progression.

View Article and Find Full Text PDF

Alpha-fetoprotein (AFP), serves as a reliable and vital biomarker for precise diagnosis and effective monitoring of hepatocellular carcinoma, requires precise detection. Herein, a sandwich-structured electrochemical immunosensor was crafted, employing three-dimensional layered porous carbon modified with gold nanoparticles (Au NPs) as the substrate and Au NPs/CuS as the labeling compound for accurate and sensitive detection of AFP. Due to the effective coordination between the 3D carbon network, Au NPs, and hollow CuS nanocubes, the sandwich-structured electrochemical immunosensor was able to produce three distinct response signals via various detection techniques, demonstrating a broad linear range (0.

View Article and Find Full Text PDF

LncRNA CRNDE and HOTAIR: Molecules behind the scenes in the progression of gastrointestinal cancers through regulating microRNAs.

Pathol Res Pract

December 2024

Medical Laboratory Technique College, the Islamic University, Najaf, Iraq; Medical Laboratory Technique College, the Islamic University of Al Diwaniyah, Al Diwaniyah, Iraq.

Gastrointestinal (GI) cancers, such as gastric cancer, hepatocellular carcinoma, colorectal cancer, and esophageal cancer, pose a significant medical and economic burden globally, accounting for the majority of new cancer cases and deaths each year. A lack of knowledge about the molecular mechanisms of GI cancers is reflected in the low efficacy of treatment for individuals with late stage and recurring illness. Understanding the molecular pathways that promote the growth of GI cancers may open doors for their therapy.

View Article and Find Full Text PDF

Hepatocellular carcinoma (HCC) is one of the most common malignancies. The currently available clinical drugs for HCC frequently cause serious side effects and the treatment outcomes are unsatisfactory. It is urgent to develop effective drugs with high selectivity and low adverse effects for HCC.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!